187 related articles for article (PubMed ID: 22947000)
21. Targeted therapies for metastatic melanoma.
Chandra S; Pavlick AC
Dermatol Clin; 2012 Jul; 30(3):517-24. PubMed ID: 22800555
[TBL] [Abstract][Full Text] [Related]
22. Targeted products yield most promising results.
Klem J; Mehr SR; Pestil Zimmerman M
Am J Manag Care; 2012 Feb; 18(1 Spec No.):SP15-8. PubMed ID: 22468867
[No Abstract] [Full Text] [Related]
23. Immunotherapy in melanoma: Recent advances and future directions.
Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
[TBL] [Abstract][Full Text] [Related]
24. Augmentation of tumor-specific immunity by upregulation of apoptotic melanoma cell calreticulin expression.
Mosca PJ; Robertson GP
Cancer Biol Ther; 2011 Mar; 11(6):581-3. PubMed ID: 21282973
[No Abstract] [Full Text] [Related]
25. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
Cavalcante L; Chowdhary A; Sosman JA; Chandra S
Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
[TBL] [Abstract][Full Text] [Related]
26. Latest developments in the treatment of melanoma: 'a penicillin moment for cancer'?
Retsas S
J R Soc Med; 2011 Jun; 104(6):269-72. PubMed ID: 21659402
[No Abstract] [Full Text] [Related]
27. Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma.
Quinn C; Ma Q; Kudlac A; Palmer S; Barber B; Zhao Z
Adv Ther; 2016 Apr; 33(4):643-57. PubMed ID: 26979173
[TBL] [Abstract][Full Text] [Related]
28. Are we entering a new era in melanoma treatment? Lesson from ASCO 2011.
Mouawad R; Spano JP; Khayat D
Melanoma Res; 2011 Oct; 21(5):377-9. PubMed ID: 21900791
[No Abstract] [Full Text] [Related]
29. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.
Dean E; Lorigan P
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1437-48. PubMed ID: 23249108
[TBL] [Abstract][Full Text] [Related]
30. Current advances and perspectives in the treatment of advanced melanoma.
Livingstone E; Zimmer L; Vaubel J; Schadendorf D
J Dtsch Dermatol Ges; 2012 May; 10(5):319-25. PubMed ID: 22432863
[TBL] [Abstract][Full Text] [Related]
31. [Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities].
Koprowska K; Czyż M
Postepy Hig Med Dosw (Online); 2011 Nov; 65():734-51. PubMed ID: 22173438
[TBL] [Abstract][Full Text] [Related]
32. Melanoma immunotherapy: historical precedents, recent successes and future prospects.
Raaijmakers MI; Rozati S; Goldinger SM; Widmer DS; Dummer R; Levesque MP
Immunotherapy; 2013 Feb; 5(2):169-82. PubMed ID: 23413908
[TBL] [Abstract][Full Text] [Related]
33. Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape.
Levine O; Devji T; Xie F
Immunotherapy; 2017 Mar; 9(5):375-378. PubMed ID: 28357918
[No Abstract] [Full Text] [Related]
34. [Targeted therapies for melanoma].
Leiter U; Meier F; Garbe C
Hautarzt; 2014 Jul; 65(7):600-6. PubMed ID: 24962553
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant immunotherapy for melanoma.
Thomas D; Bello DM
J Surg Oncol; 2021 Mar; 123(3):789-797. PubMed ID: 33595889
[TBL] [Abstract][Full Text] [Related]
36. Molecularly targeted therapies for melanoma.
Liu LS; Colegio OR
Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
[TBL] [Abstract][Full Text] [Related]
37. [Metastatic melanoma: some hope from ipilimumab and vemurafenib].
Piérard-Franchimont C; Piérard GE
Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234
[TBL] [Abstract][Full Text] [Related]
38. Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study.
Weide B; Martens A; Wistuba-Hamprecht K; Zelba H; Maier L; Lipp HP; Klumpp BD; Soffel D; Eigentler TK; Garbe C
Cancer Immunol Immunother; 2017 Apr; 66(4):441-449. PubMed ID: 28008452
[TBL] [Abstract][Full Text] [Related]
39. Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma.
Lee D; Porter J; Hertel N; Hatswell AJ; Briggs A
BioDrugs; 2016 Aug; 30(4):307-19. PubMed ID: 27177756
[TBL] [Abstract][Full Text] [Related]
40. [Unblocking antitumor immune response: novel possibilities for the immunotherapy of melanoma].
Ladányi A; Balatoni T
Magy Onkol; 2013 Jun; 57(2):100-7. PubMed ID: 23795355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]